keyword
MENU ▼
Read by QxMD icon Read
search

hepatocellular carcinoma with portal vein thrombosis

keyword
https://www.readbyqxmd.com/read/28545098/survival-and-prognostic-factors-for-patients-with-advanced-hepatocellular-carcinoma-after-stereotactic-ablative-radiotherapy
#1
Cheng-Hsiang Lo, Jen-Fu Yang, Ming-Yueh Liu, Yee-Min Jen, Chun-Shu Lin, Hsing-Lung Chao, Wen-Yen Huang
OBJECTIVE: To evaluate the survival outcomes and prognostic factors of patients with advanced hepatocellular carcinoma (HCC) who underwent stereotactic ablative radiotherapy (SABR). METHODS: This retrospective study evaluated patients with advanced HCC who underwent SABR between December 2007 and July 2015. All patients had Barcelona Clinic Liver Cancer stage C disease and Child-Turcotte-Pugh (CTP) class A-B function. In-field control (IFC), overall survival (OS), prognostic factors, and toxicity were evaluated...
2017: PloS One
https://www.readbyqxmd.com/read/28533669/prognostic-value-of-the-neutrophil-to-lymphocyte-ratio-for-hepatocellular-carcinoma-patients-with-portal-hepatic-vein-tumor-thrombosis
#2
Shao-Hua Li, Qiao-Xuan Wang, Zhong-Yuan Yang, Wu Jiang, Cong Li, Peng Sun, Wei Wei, Ming Shi, Rong-Ping Guo
AIM: To investigate whether the preoperative neutrophil-to-lymphocyte ratio (NLR) could predict the prognosis of hepatocellular carcinoma (HCC) patients with portal/hepatic vein tumor thrombosis (PVTT/HVTT) after hepatectomy. METHODS: The study population included 81 HCC patients who underwent hepatectomy and were diagnosed with PVTT/HVTT based on pathological examination. The demographics, laboratory analyses, and histopathology data were analyzed. RESULTS: Overall survival (OS) and disease-free survival (DFS) were determined in the patients with a high (> 2...
May 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28507925/stratified-platelet-to-lymphocyte-ratio-a-novel-target-for-prognostic-prediction-of-hepatocellular-carcinoma-after-curative-liver-resection
#3
Gui-Qian Huang, Ji-Na Zheng, Tian-Tian Zou, Yi-Ran Chen, Ke-Qing Shi, Sven Van Poucke, Zhang Cheng, Lu-Yi Ruan, Ming-Hua Zheng
Background and Aims: Platelet-to-lymphocyte ratio (PLR) has been shown to predict prognosis of cancers. We aimed to evaluate the prognostic value of stratification of PLR in patients after curative liver resection (CLR) for hepatocellular carcinoma (HCC). Methods: A total of 1804 patients who underwent CLR for suspected HCC between January 2007 and January 2014 were screened for the study. All of the patients were categorized into equal tertiles according to the number of patients and the distribution of PLR...
March 28, 2017: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/28506055/clinical-features-and-outcomes-of-patients-with-hepatocellular-carcinoma-complicated-with-bile-duct-invasion
#4
Jihyun An, Kwang Sun Lee, Kang Mo Kim, Do Hyun Park, Sang Soo Lee, Danbi Lee, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee
Background/Aims: Little is known about the treatment or outcomes of hepatocellular carcinoma (HCC) complicated with bile duct invasion. Methods: A total of 247 consecutive HCC patients with bile duct invasion at initial diagnosis were retrospectively included. Results: The majority of patients had Barcelona Clinic Liver Cancer (BCLC) stage C HCC (66.8%). Portal vein tumor thrombosis was present in 166 (67.2%) patients. Median survival was 4...
May 16, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28494528/a-comparative-study-of-sorafenib-and-metronomic-chemotherapy-for-barcelona-clinic-liver-cancer-stage-c-hepatocellular-carcinoma-with-poor-liver-function
#5
Hyun Yang, Hyun Young Woo, Soon Kyu Lee, Ji Won Han, Bohyun Jang, Hee Chul Nam, Hae Lim Lee, Sung Won Lee, Do Seon Song, Myeong Jun Song, Jung Suk Oh, Ho Jong Chun, Jeong Won Jang, Angelo Lozada, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
Background/Aims: Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT). Methods: A total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients who had undergone sorafenib therapy were analyzed as the control group...
May 10, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28486226/role-of-albumin-in-growth-inhibition-in-hepatocellular-carcinoma
#6
Ezgi Bağırsakçı, Eren Şahin, Neşe Atabey, Esra Erdal, Vito Guerra, Brian I Carr
OBJECTIVE: Levels of serum albumin have recently emerged, together with C-reactive protein, as an important prognostic indicator for hepatocellular carcinoma (HCC). It has recently been reported that larger HCCs are associated with lower albumin levels. However, the albumin-mediated growth decrease has yet to be determined. METHODS: We examined a large HCC cohort and then by direct exposure of HCC cells in vitro, the relationship of albumin levels to HCC growth...
May 10, 2017: Oncology
https://www.readbyqxmd.com/read/28480062/locoregional-and-systemic-therapy-for-hepatocellular-carcinoma
#7
REVIEW
Olumide B Gbolahan, Michael A Schacht, Eric W Beckley, Thomas P LaRoche, Bert H O'Neil, Maximilian Pyko
The management of hepatocellular carcinoma (HCC) remains challenging due to late presentation and the presence of accompanying liver dysfunction. As such, most patients are not eligible for curative resection and liver transplant. Management in this scenario depends on a number of factors including hepatic function, tumor burden, patency of hepatic vasculature and patients' functional status. Based on these, patients can be offered catheter based intra-arterial therapy for intermediate stage disease and in more advanced disease, sorafenib...
April 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28467966/combination-treatment-with-transarterial-chemoembolization-radiotherapy-and-hyperthermia-cert-for-hepatocellular-carcinoma-with-portal-vein-tumor-thrombosis-final-results-of-a-prospective-phase-ii-trial
#8
Jeong Il Yu, Hee Chul Park, Sang Hoon Jung, Changhoon Choi, Sung Wook Shin, Sung Ki Cho, Dong Hyun Sinn, Yong-Han Paik, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Byung Chul Yoo, Hüseyin Sahinbas, Seung Woon Paik
BACKGROUND & AIMS: This study was designed to evaluate the efficacy and safety of combination transarterial chemoembolization (TACE) followed by radiotherapy (RT) and hyperthermia (CERT) in hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). METHODS: This single-institution, single-arm, prospective phase II study was performed from October 2013 to February 2016. The objective response rate (ORR) was evaluated at 3 months after CERT completion, and overall ORR was the primary end point...
April 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/28466374/the-outcome-of-sorafenib-monotherapy-on-hepatocellular-carcinoma-with-portal-vein-tumor-thrombosis
#9
Yuan-Hung Kuo, I-Pei Wu, Jing-Houng Wang, Chao-Hung Hung, Kun-Ming Rau, Chien-Hung Chen, Kwong-Ming Kee, Tsung-Hui Hu, Sheng-Nan Lu
Sorafenib is not recommended for advanced hepatocellular carcinoma (HCC) patients with Vp4 (portal invasion at the main trunk) by the Japan Society of Hepatology (JSH) due to a risk of hepatic failure. This study aimed to elucidate the safety and efficacy of sorafenib monotherapy on HCC with macro-vascular invasion (MVI). A total of 415 consecutive advanced HCC patients received sorafenib in our hospital. Patients with only MVI and sorafenib monotherapy were retrospectively enrolled. We enrolled 113 (27.2%) patients, including 56 (49...
May 2, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28447055/associating-liver-partition-and-portal-vein-ligation-for-bleeding-hepatocellular-carcinoma-in-hbv-cirrhosis-a-safety-strategy
#10
Giovanni Battista Levi Sandri, Giovanni Vennarecci, Pasquale Lepiane, Giuseppe Maria Ettorre
The incidence of hepatocellular carcinoma (HCC) spontaneous tumor rupture varies between 3% and 26%. For resectable HCC ruptures, emergency hepatectomy or staged hepatectomy after transcatheter arterial embolization (TAE) are life-saving procedures, and efficient therapeutic methods. We report a multimodal therapy including TAE, associating liver partition and portal vein ligation (ALPPS) and immunoglobuline infusion for a huge bleeding HCC with portal vein tumor thrombosis (PVTT) in hepatitis B virus (HBV) cirrhosis...
2017: Translational Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28438885/prognostic-nomograms-stratify-survival-of-patients-with-hepatocellular-carcinoma-without-portal-vein-tumor-thrombosis-after-curative-resection
#11
Yi-Peng Fu, Yong Yi, Jin-Long Huang, Chu-Yu Jing, Jian Sun, Xiao-Chun Ni, Zhu-Feng Lu, Ya Cao, Jian Zhou, Jia Fan, Shuang-Jian Qiu
BACKGROUND: The prognosis of patients with hepatocellular carcinoma (HCC) without portal vein tumor thrombosis (PVTT) after curative resection is at variance. We identified the risk factors of poor postoperative prognosis and consequently developed prognostic nomograms generating individual risk of death and recurrence for this subgroup of patients with HCC. METHODS: The risk factors were identified and nomograms were developed based on a retrospective study of 734 patients in the primary cohort who underwent curative resection for HCC from 2010 to 2012...
May 2017: Oncologist
https://www.readbyqxmd.com/read/28420555/chemoembolization-for-hepatocellular-carcinoma-in-patients-with-extrahepatic-spread-prognostic-determinants-and-appropriate-candidates
#12
Enxin Wang, Lei Liu, Dongdong Xia, Wenjun Wang, Wei Bai, Qiuhe Wang, Jie Yuan, Xiaomei Li, Lei Zhang, Jing Niu, Zhanxin Yin, Jielai Xia, Hongwei Cai, Daiming Fan, Guohong Han
PURPOSE: To investigate treatment outcome, prognostic factors for overall survival, and appropriate candidates for transarterial chemoembolization among patients with hepatocellular carcinoma (HCC) and extrahepatic spread (EHS). MATERIALS AND METHODS: From January 2010 to June 2014, 111 consecutive patients with HCC and EHS treated by transarterial chemoembolization alone were evaluated. Factors associated with overall survival were evaluated using Cox regression analysis, and a scoring equation was established to subgroup patients with EHS...
April 15, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28396192/safety-and-efficacy-of-irradiation-stent-placement-for-malignant-portal-vein-thrombus-combined-with-transarterial-chemoembolization-for-hepatocellular-carcinoma-a-single-center-experience
#13
Jian Lu, Jin-He Guo, Hai-Dong Zhu, Guang-Yu Zhu, Li Chen, Gao-Jun Teng
PURPOSE: To assess feasibility, safety, and preliminary efficacy of an irradiation portal vein stent for portal vein tumor thrombosis (PVTT) in patients with hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Between October 2012 and September 2015, 25 of 40 patients (mean age of 55.5 y) with PVTT caused by HCC were recruited for treatment with an irradiation portal vein stent (self-expandable stent loaded with iodine-125 seeds) at a single hospital. Liver function was classified as Child-Pugh class A in 15 patients (60%) and class B in 10 patients (40%)...
April 7, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28364812/coagulopathy-before-and-after-liver-transplantation-from-the-hepatic-to-the-systemic-circulatory-systems
#14
REVIEW
Jonathan G Stine, Patrick G Northup
The hemostatic environment in patients with cirrhosis is a delicate balance between prohemostatic and antihemostatic factors. There is a lack of effective laboratory measures of the hemostatic system in patients with cirrhosis. Many are predisposed to pulmonary embolus, deep vein thrombosis, and portal vein thrombosis in the pretransplantation setting. This pretransplantation hypercoagulable milieu seems to extend for at least several months post-transplantation. Patients with nonalcoholic fatty liver disease, inherited thrombophilia, portal hypertension in the absence of cirrhosis, and hepatocellular carcinoma often require individualized approach to anticoagulation...
May 2017: Clinics in Liver Disease
https://www.readbyqxmd.com/read/28356989/sorafenib-therapy-following-resection-prolongs-disease-free-survival-in-patients-with-advanced-hepatocellular-carcinoma-at-a-high-risk-of-recurrence
#15
Yadi Liao, Yun Zheng, Wei He, Qijiong Li, Jingxian Shen, Jian Hong, Ruhai Zou, Jiliang Qiu, Binkui Li, Yunfei Yuan
Sorafenib is the standard systemic treatment for patients with advanced hepatocellular carcinoma (HCC); however, its therapeutic value in patients with HCC following resection remains controversial. The current retrospective study was undertaken to assess the effects of sorafenib treatment following surgical resection in patients with advanced HCC disease who were at a high risk for recurrence. Between July 2010 and July 2013, a consecutive cohort of 42 patients with advanced HCC and at a high risk of recurrence (i...
February 2017: Oncology Letters
https://www.readbyqxmd.com/read/28355956/hepatocellular-carcinoma-in-danish-patients-a-single-copenhagen-center-experience
#16
Jenna Stefansdottir, Erik Christensen, Frank Vinholt Schiødt
OBJECTIVE: Hepatocellular carcinoma (HCC) is a common cause of cancer, and most HCC patients have underlying cirrhosis. Retrospectively, we aimed to characterize patients with newly diagnosed HCC at a Danish hospital and to investigate survival and identify predictive factors for survival. METHODS: All patients diagnosed with HCC from January 2008 to December 2014 were retrospectively enrolled in this study. Overall survival was estimated by using the Kaplan-Meier method...
June 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28349781/evaluation-of-sorafenib-in-chinese-unresectable-hepatocellular-carcinoma-patients-with-prior-surgery-and-portal-vein-tumor-thrombosis-a-subset-analysis-of-gideon-study-data
#17
MULTICENTER STUDY
Sheng-Long Ye, Xiaoping Chen, Jiamei Yang, Ping Bie, Shuijun Zhang, Fengyong Liu, Luming Liu, Jie Zhou, Kefeng Dou, Christina Sm Yip, Xiaolei Yang
The purpose of this study was to examine the safety and efficacy of sorafenib in Chinese patients with unresectable hepatocellular carcinoma. Data of 338 Chinese patients from the Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib study database were included. Patients were divided into those who received and did not receive sorafenib prior to surgical resection and those with and without portal vein tumor thrombosis. In the non-surgery group, the median survival was 302 days (95% confidence interval: 244-371), and the median time from diagnosis to death was 428 days (95% confidence interval: 352-556); in the surgery group, half of the patients survived for 345 days and the median time from diagnosis to death was 1000 days (95% confidence interval: 750-2816)...
March 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28240515/portal-vein-thrombosis-in-unresectable-hcc-cases-a-single-center-study-of-prognostic-factors-and-management-in-140-patients
#18
Ahmed Hosni Abdelmaksoud, Safaa Mandooh, Mohamed Mahmoud Nabeel, Tamer Mahmoud Elbaz, Hend Ibrahim Shousha, Ashraf Monier, Inas Anwar Elattar, Ashraf Omar Abdelaziz
Objective: Hepatocellular carcinoma with portal vein thrombosis is considered a relative contraindication for transarterial chemoembolization (TACE). The aim of our study was to evaluate the prognostic factors and management in patients with hepatocellular carcinoma with portal vein thrombosis (PVT). Methods: Between February 2011 and February 2015, 140 patients presented to our specialized multidisciplinary HCC clinic. All were assessed by imaging at regular intervals for tumor response and the data compared with baseline laboratory and imaging characteristics obtained before treatment...
January 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28228906/histological-assessment-of-the-efficacy-of-drug-eluting-beads-in-portal-tumor-thrombosis-of-hepatocellular-carcinoma
#19
Yusuke Imai, Masashi Hirooka, Yohei Koizumi, Yoshiko Nakamura, Takao Watanabe, Osamu Yoshida, Yoshio Tokumoto, Eiji Takeshita, Masanori Abe, Hiroaki Tanaka, Mie Kurata, Sohei Kitazawa, Yoichi Hiasa
A 58-year-old man was diagnosed with advanced hepatocellular carcinoma with portal vein tumor thrombosis (PVTT). The tumors were multiple and existed in both lobes. Drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) was performed for the tumors in the left lobe. Embosphere and Hepasphere were selected for embolization of the arterioportal shunt, followed by loaded epirubicin infusion into the left hepatic artery. Computed tomography showed reduction of PVTT. However, liver failure progressed, and the patient died 67 days after DEB-TACE...
March 2017: Radiology case reports
https://www.readbyqxmd.com/read/28223736/percutaneous-electrochemotherapy-in-the-treatment-of-portal-vein-tumor-thrombosis-at-hepatic-hilum-in-patients-with-hepatocellular-carcinoma-in-cirrhosis-a-feasibility-study
#20
Luciano Tarantino, Giuseppina Busto, Aurelio Nasto, Raffaele Fristachi, Luigi Cacace, Maria Talamo, Catello Accardo, Sara Bortone, Paolo Gallo, Paolo Tarantino, Riccardo Aurelio Nasto, Matteo Nicola Dario Di Minno, Pasquale Ambrosino
AIM: To treated with electrochemotherapy (ECT) a prospective case series of patients with liver cirrhosis and Vp3-Vp4- portal vein tumor thrombus (PVTT) from hepatocellular carcinoma (HCC), in order to evaluate the feasibility, safety and efficacy of this new non thermal ablative technique in those patients. METHODS: Six patients (5 males and 1 female), aged 61-85 years (mean age, 70 years), four in Child-Pugh A and two in Child-Pugh B class, entered our study series...
February 7, 2017: World Journal of Gastroenterology: WJG
keyword
keyword
77310
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"